Brokerages Set Century Therapeutics, Inc. (NASDAQ:IPSC) Target Price at $10.00

Shares of Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) have earned an average recommendation of "Buy" from the six ratings firms that are covering the firm, MarketBeat reports. Six investment analysts have rated the stock with a buy recommendation. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $10.00.

Several research firms have issued reports on IPSC. Guggenheim restated a "buy" rating on shares of Century Therapeutics in a research report on Wednesday, January 22nd. Piper Sandler lowered their price target on shares of Century Therapeutics from $12.00 to $4.00 and set an "overweight" rating on the stock in a report on Monday, December 30th. Chardan Capital lowered their target price on shares of Century Therapeutics from $17.00 to $11.00 and set a "buy" rating on the stock in a research note on Thursday, November 7th. Finally, HC Wainwright restated a "buy" rating and set a $5.00 price target on shares of Century Therapeutics in a research report on Wednesday, January 22nd.

Century Therapeutics Stock Performance

NASDAQ:IPSC traded down $0.01 during trading hours on Friday, reaching $0.76. The stock had a trading volume of 448,522 shares, compared to its average volume of 491,439. Century Therapeutics has a 12-month low of $0.68 and a 12-month high of $5.51. The stock has a 50 day simple moving average of $0.95 and a 200 day simple moving average of $1.33. The stock has a market cap of $64.48 million, a P/E ratio of -0.41 and a beta of 1.73.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Casdin Capital LLC raised its position in Century Therapeutics by 61.6% in the 4th quarter. Casdin Capital LLC now owns 5,190,506 shares of the company's stock worth $5,242,000 after purchasing an additional 1,978,190 shares during the period. Millennium Management LLC increased its holdings in shares of Century Therapeutics by 1,041.8% in the fourth quarter. Millennium Management LLC now owns 1,607,174 shares of the company's stock worth $1,623,000 after buying an additional 1,466,415 shares during the period. Renaissance Technologies LLC lifted its stake in shares of Century Therapeutics by 146.4% in the 4th quarter. Renaissance Technologies LLC now owns 1,202,885 shares of the company's stock valued at $1,215,000 after acquiring an additional 714,685 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Century Therapeutics by 2.4% during the 4th quarter. Geode Capital Management LLC now owns 991,595 shares of the company's stock valued at $1,002,000 after acquiring an additional 23,413 shares during the period. Finally, State Street Corp grew its position in Century Therapeutics by 7.4% during the 3rd quarter. State Street Corp now owns 836,914 shares of the company's stock worth $1,431,000 after acquiring an additional 57,323 shares during the last quarter. 50.20% of the stock is owned by hedge funds and other institutional investors.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.